A pilot study of urokinase therapy in cerebral infarction

Anthony P. Fletcher, Norma Alkjaersig, Martin Lewis, Vasil Tulevski, Andrew Davies, John E. Brooks, William B. Hardin, William M. Landau, Marcus E. Raichle

Research output: Contribution to journalArticlepeer-review

173 Scopus citations


Thirty-one patients with acute cerebral infarction were treated with the thrombolytic agent urokinase for either a single or a double infusion period, each of ten hours. The effects of urokinase therapy administered at dosage rates of 1,200, 1.500 or 1,700 (TA urokinase units per pound of body weight per hour were followed by serial blood coagulation and other biochemical studies. In the dosage used, urokinase produced a prompt sustained increase, 20-fold to 40-fold, of plasma thrombolytic activity with relatively minor disturbance of the blood coagulation system. Never-theless. hemorrhagic complications occurred in several patients and distinctly favorable therapeutic effects were not observed.

Original languageEnglish
Pages (from-to)135-142
Number of pages8
Issue number2
StatePublished - 1976


Dive into the research topics of 'A pilot study of urokinase therapy in cerebral infarction'. Together they form a unique fingerprint.

Cite this